Taken together the MICE of vanoxerine in a background of normal or increased hERG surface expression may account for the absence of proarrhythmic effects and termination of AF/AFL in clinical trials3 as predicted by our nonclinical hypothesis. This evidence concerns the gene KCNH2 and atrial fibrillation.